Versantis
Multiorgan support for rare pediatric and acute liver diseases
Multiorgan support for rare pediatric and acute liver diseases
Versantis is a clinical-stage pharmaceutical company that aims to revolutionize the care of patients with liver and rare pediatric diseases. Founded in 2015, the company's mission is to provide multiorgan support for rare pediatric and acute liver diseases. Versantis has recently received a significant investment of Fr.475.00K in the form of a grant from Innosuisse, indicating a strong interest in the company's innovative approach. The company focuses on addressing unmet medical needs in emergency care, particularly aiming to support acute decompensations of cirrhosis and save infants born with rare genetic disorders. Versantis operates within the health care and pharmaceutical industries, positioning itself as a key player in advancing treatment options for these critical medical conditions.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | Fr.475.00K | 1 |
|
13 Apr 2022 |
| Series B | Fr.16.00M | 6 |
|
18 Sep 2019 |
| Series A | Fr.4.40M | 6 |
|
29 Mar 2017 |
| Non Equity Assistance | Fr.100.00K | 1 |
|
02 Nov 2016 |
| Seed Round | Fr.100.00K | 1 |
|
21 Jan 2015 |
No recent news or press coverage available for Versantis.
We care about your data, and we'd love to use cookies make your experience better.
